21 Biotechnology Stocks to Buy Now

21 Biotechnology Stocks to Buy Now

This week, 21 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, Biogen Inc.’s (BIIB) ratings are up from a C last week to a B. Biogen Inc. is a global biotechnology company that meets the needs of therapeutic care providers and recipients. The company also gets A’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BIIB stock.

Five Prime Therapeutics, Inc. (FPRX) gets a higher grade this week, advancing from a B last week to a A. The company also gets A’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FPRX stock.

This is a strong week for Repligen Corporation (RGEN). The company’s rating climbs to B from the previous week’s C. Repligen Corporation is a biopharmaceutical company that develops therapeutics for radiology and neuropsychiatry. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of RGEN stock.

This week, MacroGenics, Inc. (MGNX) pushes up from a C to a B rating. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MGNX stock.

The rating of Xencor, Inc. (XNCR) moves up this week, rising from a B to a A. The company also gets A’s in sales growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of XNCR stock.

Retrophin, Inc. (RTRX) improves from a C to a B rating this week. The company also gets A’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of RTRX stock.

Bellicum Pharmaceuticals Inc (BLCM) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of BLCM stock.

Exact Sciences Corporation (EXAS) shows solid improvement this week. The company’s rating rises from a B to a A. Exact Sciences Corporation is a molecular diagnostics company, focuses on developing a molecular diagnostic technology for the early detection and prevention of colorectal pre-cancer and cancer. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of EXAS stock.

Stemline Therapeutics, Inc. (STML) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of STML stock.

Natera, Inc.’s (NTRA) ratings are looking better this week, moving up to a B from last week’s C. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of NTRA stock.

Inovio Pharmaceuticals, Inc. (INO) boosts its rating from a C to a B this week. Inovio Pharmaceuticals, Inc. engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. For more information, get Portfolio Grader’s complete analysis of INO stock.

Aldeyra Therapeutics, Inc.’s (ALDX) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

This week, Agenus Inc.’s (AGEN) ratings are up from a C last week to a B. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

Progenics Pharmaceuticals, Inc. (PGNX) earns a B this week, jumping up from last week’s grade of C. Progenics Pharmaceuticals, Inc. develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company also gets A’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Array BioPharma Inc. (ARRY) is seeing ratings go up from a D last week to a B this week. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

Vital Therapies, Inc. (VTL) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of VTL stock.

Sinovac Biotech Ltd. (SVA) improves from a C to a B rating this week. Sinovac Biotech Ltd. researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. For more information, get Portfolio Grader’s complete analysis of SVA stock.

Kindred Biosciences, Inc. (KIN) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of KIN stock.

This week, Aurinia Pharmaceuticals Inc. (AUPH) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of AUPH stock.

The rating of Curis, Inc. (CRIS) moves up this week, rising from a C to a B. Curis, Inc. is a drug discovery and development company that engages in the research and development of cancer therapeutics. For more information, get Portfolio Grader’s complete analysis of CRIS stock.

This is a strong week for Athersys, Inc. (ATHX). The company’s rating climbs to A from the previous week’s B. Athersys, Inc. is a biopharmaceutical company that engages in the discovery and development of therapeutic products in various disease areas in the United States. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of ATHX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/21-biotechnology-stocks-to-buy-now/.

©2019 InvestorPlace Media, LLC